Excelsior Biopharma Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 175.52 million compared to TWD 300.65 million a year ago. Net loss was TWD 10.05 million compared to TWD 12.55 million a year ago. Basic loss per share from continuing operations was TWD 0.22 compared to TWD 0.27 a year ago. Diluted loss per share from continuing operations was TWD 0.22 compared to TWD 0.27 a year ago.
For the nine months, sales was TWD 504.49 million compared to TWD 971.34 million a year ago. Net loss was TWD 32.62 million compared to TWD 12.89 million a year ago. Basic loss per share from continuing operations was TWD 0.71 compared to TWD 0.28 a year ago. Diluted loss per share from continuing operations was TWD 0.71 compared to TWD 0.28 a year ago.